Regenxbio (RGNX) Net Income (2014 - 2026)
Regenxbio (RGNX) posted quarterly Net Income of $89.8 million for Q4 2025, up 234.83% year-over-year from $26.8 million in Q4 2024, and up 237.17% quarter-over-quarter from -$65.5 million in Q3 2025.
Regenxbio (RGNX) Net Income (2014 - 2026) Analysis & Trends
Regenxbio's Net Income history runs 12 years deep, the most recent figure standing at $89.8 million for Q4 2025.
- In Q4 2025, Net Income rose 234.83% year-over-year to $89.8 million; the TTM figure through Dec 2025 stood at -$43.0 million (up 83.11% YoY), while the FY2025 annual figure was -$535.6 million, down 132.24% from the prior year.
- Net Income for Q4 2025 stood at $89.8 million, up from -$65.5 million in the prior quarter.
- The five-year high for Net Income was $294.0 million in Q4 2021, with the low at -$76.7 million in Q1 2022.
- The 5-year median for Net Income is -$62.4 million (2023), against an average of -$18.7 million.
- Peak annual rise in Net Income reached 735.85% in 2021, while the deepest fall reached 764.37% in 2021.
- Regenxbio's Net Income stood at $294.0 million in 2021, then declined by 5.04% to $279.2 million in 2022, then sank by 122.55% to -$63.0 million in 2023, then retreated by 5.8% to -$66.6 million in 2024, then jumped by 234.83% to $89.8 million in 2025.
- Business Quant data shows RGNX's Net Income at $89.8 million in Q4 2025, -$65.5 million in Q3 2025, and -$70.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | 18.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.76 Mn |
| Dec 31, 2025 | 89.82 Mn |
| Sep 30, 2025 | -65.48 Mn |
| Jun 30, 2025 | -70.89 Mn |
| Mar 31, 2025 | 3.54 Mn |
| Dec 31, 2024 | -66.62 Mn |
| Sep 30, 2024 | -60.10 Mn |
| Jun 30, 2024 | -54.09 Mn |
| Mar 31, 2024 | -73.95 Mn |
| Dec 31, 2023 | -62.97 Mn |
| Sep 30, 2023 | -61.87 Mn |
| Jun 30, 2023 | -72.06 Mn |
| Mar 31, 2023 | -66.68 Mn |
| Dec 31, 2022 | 279.21 Mn |
| Sep 30, 2022 | -75.48 Mn |
| Jun 30, 2022 | -68.18 Mn |
| Mar 31, 2022 | -76.72 Mn |
| Dec 31, 2021 | 294.02 Mn |
| Sep 30, 2021 | -58.41 Mn |
| Jun 30, 2021 | -57.64 Mn |